Noninvasive fetal RhD genotyping.

Area of Science:

• Maternal-fetal medicine
• Genetics
• Immunology

Background:

• Hemolytic disease of the fetus and newborn (HDFN) is primarily caused by RhD immunization.
• Immune prophylaxis has reduced RhD immunization, but antenatal prophylaxis is given broadly due to unknown fetal RhD status.
• A significant proportion of D-negative women carry D-negative fetuses, thus not requiring prophylaxis.

Purpose of the Study:

• To evaluate the utility of noninvasive fetal RhD genotyping for targeted antenatal prophylaxis.
• To reduce unnecessary treatment in D-negative pregnant women.
• To assess the risk of HDFN in anti-D immunized women.

Main Methods:

• Analysis of cell-free fetal DNA from maternal plasma for RhD genotyping.
• Implementation of fetal RhD genotyping as a screening assay.
• Utilizing gestational age for assay sensitivity assessment.

Main Results:

• Noninvasive fetal RhD genotyping demonstrates high sensitivity (>99.3%) from 10-11 weeks of gestation.
• This method enables targeted antenatal prophylaxis for women carrying D-positive fetuses.
• Fetal RhD genotyping is effective in assessing HDFN risk for anti-D immunized women.

Conclusions:

• Noninvasive fetal RhD genotyping allows for precise targeting of antenatal prophylaxis, avoiding unnecessary treatment.
• This technique significantly improves the management of RhD-negative pregnancies.
• Fetal RhD status determination is crucial for preventing HDFN and optimizing maternal care.